

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTORNEY DOCKET NO. PU4725USW	INTERNATIONAL APP. NO. 108510542 PCT/US03/10747
	APPLICANT Spector et al.	
	INTERNATIONAL FILING DATE 4/8/03	GROUP

U.S. PATENT DOCUMENTS

Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
/JDA/	1	6,727,256	4/27/04	Carter et al.			
	2	6,713,485	3/30/04	Carter et al.			
	3	6,169,091	1/2/01	Cockerill et al.			
	4	6,174,889	1/16/01	Cockerill et al.			
	5	6,723,726	4/20/04	Cockerill et al.			
	6	6,207,669	3/27/01	Cockerill et al.			
/JDA/	7	6,391,874	5/21/02	Cockerill et al.			

Continue on page \_\_\_\_\_

FOREIGN PATENT DOCUMENTS

		Document Number	Publication Date	Country	Class	Subclass	Translation Yes I No
/JDA/	8	02/056912	7/25/02	PCT			

Continue on page \_\_\_\_\_

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

/JDA/	9	Martinez-Lacaci, E.A., "RAS transformation causes sustained activation of epidermal growth factor receptor and elevation of mitogen-activated protein kinase in human mammary epithelial cells," <u>International Journal of Cancer</u> , Vol. 88, No. 1, 2000, pp. 44-52.
/JDA/	10	He, E.A., "Signal therapy for RAS-induced cancers in combination of AG 879 and PP1, specific inhibitors for ErbB2 and Src family kinases, that block PAK activation," <u>Cancer Journal</u> , Vol. 7, No. 3, 2001, pp. 191-202.

Continue on page \_\_\_\_\_

EXAMINER /James Anderson/	DATE CONSIDERED 04/16/2007
------------------------------	-------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.